Anzeige
Mehr »
Donnerstag, 12.03.2026 - Börsentäglich über 12.000 News
Dieser 37-Mio.-€-Goldentwickler sitzt auf einem möglichen $2-Milliarden-Projekt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
926 Leser
Artikel bewerten:
(2)

dipylonmedical: Dipylon Medical Expands Access to Clinical Microbiology Equipment for Modern Diagnostic Laboratories

Expanding access to advanced PCR thermocyclers, DNA & RNA purification systems, and hematology analyzers for modern clinical laboratories

SINGAPORE, SG / ACCESS Newswire / March 7, 2026 / Dipylon Medical, a specialized provider of laboratory and diagnostic technologies, today announced the expansion of its portfolio of clinical microbiology and molecular diagnostic equipment, supporting laboratories, hospitals, and research institutions with advanced tools for infectious disease detection and biomedical research.

The expansion reflects growing global demand for molecular diagnostics, microbiology testing, and automated laboratory workflows, as healthcare systems increasingly rely on precision testing to detect pathogens, monitor outbreaks, and guide treatment decisions.

Clinical microbiology technologies-including PCR thermocyclers, DNA and RNA purification systems, and hematology analyzers-play a central role in modern laboratory diagnostics, enabling faster and more accurate identification of microorganisms and antimicrobial resistance.

"Laboratory diagnostics is entering a new era driven by automation, molecular biology, and high-throughput testing," said CEO, Kimberly Steckler "Our mission is to help laboratories access reliable, high-performance equipment that supports accurate diagnostics and improved patient care."

Growing Importance of Clinical Microbiology Technologies

Recent developments in the diagnostics industry highlight the strategic importance of microbiology testing and molecular diagnostics. In one notable example, Beckman Coulter announced an agreement to acquire the clinical microbiology business of Siemens Healthcare Diagnostics, including its MicroScan systems used for microbial identification and antibiotic susceptibility testing.

These systems help laboratories identify microorganisms and determine antibiotic sensitivity, providing clinicians with critical information for managing infectious diseases and combating antimicrobial resistance.

Industry consolidation and investment in microbiology technologies reflect the expanding role of laboratory diagnostics in modern healthcare.

Advanced Diagnostic Equipment for Modern Laboratories

Dipylon Medical supplies a wide range of laboratory technologies designed for clinical microbiology, molecular biology, and diagnostic research, including:

  1. PCR Thermocyclers for DNA amplification and pathogen detection

  2. DNA & RNA Purification Systems for molecular research and sequencing preparation

  3. Hematology Analyzers for automated blood analysis

  4. Supporting modern laboratories with clinical chemistry analyzers.

  5. Expanding access to PCR thermocycler for modern diagnostic laboratories.

These systems are used across hospitals, diagnostic laboratories, biotechnology research facilities, and pharmaceutical companies.

Supporting the Future of Molecular Diagnostics

Advances in molecular diagnostics are transforming the way laboratories detect and monitor infectious diseases. Technologies such as PCR testing and automated nucleic acid purification have become essential tools in identifying viral, bacterial, and genetic conditions.

As global healthcare systems continue to prioritize early detection and precision medicine, laboratories are investing in equipment that can deliver fast turnaround times, high accuracy, and scalable testing capacity.

Dipylon Medical aims to support this transformation by providing access to trusted diagnostic technologies and laboratory equipment from leading manufacturers.

"Reliable laboratory equipment is the foundation of accurate diagnostics," the company added. "By supplying advanced microbiology and molecular biology systems, we help laboratories deliver faster results and better outcomes for patients."

About Dipylon Medical

Dipylon Medical is a supplier of clinical microbiology and laboratory diagnostic equipment, serving hospitals, research laboratories, and healthcare institutions worldwide. The company specializes in technologies for molecular biology, microbiology testing, and automated laboratory workflows, including PCR thermocyclers, DNA and RNA purification systems, and hematology analyzers.

Through its global network and industry expertise, Dipylon Medical supports laboratories with reliable diagnostic solutions that enhance research, clinical testing, and patient care.

Learn more:
https://dipylonmedical.com/about/

Media Contact

Kim Lee
Public Relation Manager
Dipylon Medical
+1812-768-6999
Email: sales@dipylonmedical.com
Website: https://dipylonmedical.com/

SOURCE: Dipylon Medical



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/dipylon-medical-expands-access-to-clinical-microbiology-equipment-for-1144950

© 2026 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.